SAINT PETERSBURG, FL, Oct. 15, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Apotheca Biosciences (OTC PINK: PCFP), a developer of
cutting-edge medical products, nutraceuticals, drug formulations and cannabis delivery technologies for the healthcare and consumer
care industry announces today, with greatest honor, the addition of Dr. Malireddy Srinivasulu Reddy (M.S. Reddy), Seven Time Nobel
Prize Nominee, to the Apotheca Bioscience’s research team as Chief Medical Advisor.
Dr. Reddy has received his BVSc. degree from A.P. Agricultural University, M.S. and PhD degrees in food technology, bacteriology
and virology, from Iowa State University with honors and distinctions. He currently serves as Chairman and President of U.S. based
American Dairy and Food Consulting Laboratories, and International Media and Cultures. Dr. Reddy was nominated for the Nobel Peace
Prize in 2012 and is well-known globally for his work in the field of applied microbiology. He has received numerous national and
international awards and honors from all over the world. A few of the notable awards are: Richard M. Hoyt Memorial, Outstanding
Young Alumnus Recognition, Outstanding Scientist, Outstanding Businessman of the year and the prestigious U.S. President Ronald
Regan Gold Medal Award.
In addition to the numerous accolades and awards that Dr. Reddy has received, he also holds over 150 U.S. and international
patents, published over 70 scientific articles and has written several popular books. Due to his robust experience in applied
microbiology, he is a leading authority as is it relates to dairy foods, probiotics and pollution mitigation. More than 100 of his
company’s patented high-tech products are used in commerce globally. Dr. Reddy has also helped to improve the world economy by
increasing food production, reducing food spoilage and food prices though significant scientific inventions. He has also published
over 120 research articles on probiotics applicable to medical and food industry
“I’m excited to welcome M.S. Reddy to the research team of Apotheca Biosciences,” said John Verghese, Chief Technology Officer
at Apotheca Biosciences. He provides a great blend of education and knowledge that will undoubtedly have an impact on patient’s
lives.
Apotheca Biosciences is at the forefront of medical technologies with the development of a CBD pain patch for the healthcare and
consumer care industry. We look forward to the knowledge and expertise that Dr. Reddy will bring to the development of this
product, along with our other products. Our pipeline of products includes transdermal, sublingual, and nasal delivery technologies
for precise and controlled dosing of cannabinoids.
About Apotheca Biosciences: Apotheca Biosciences is a pioneering biotech company with an emphasis in research and development in
addition to the creation of high-grade nutraceuticals and cosmetics. The health of our customers takes precedence and our solid
business strategy ensures focus on customer well-being. Our goal is to lay the groundwork and continue research of cannabinoid
receptiveness in patients and create nutraceuticals that reflects our strategy and research. For more information on Apotheca
Biosciences, please visit www.apothecabio.com or www.apothecabio.com.
Apotheca Biosciences is developing revolutionary formulas and medical delivery systems to transform treatment methods from Pain
relief to Alzheimer. With the growing understanding of the effectiveness of CBD, it is impossible not to be a part of the growing
CBD industry and Apotheca Biosciences will be at the forefront.
About Apotheca Biosciences Inc.
Apotheca is a developer of cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the
healthcare and consumer care industry. Its pipeline of products includes, transdermal, sublingual, and nasal delivery technologies
for precise and controlled dosing of cannabinoids. Apotheca believes that it can deliver meaningful benefits using its technologies
to the world’s aging population.
To request further information about Apotheca, please email info@apothecabio.com, or visit its website at http://www.apothecabiosciences.com/, or visit it on FB @apotheca and Twitter @apotheca
Forward-Looking Statements
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement
of our services and products, statements about future market conditions, supply and demand conditions, and other expectations,
intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our
expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce
today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar
expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a
number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This
release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the
Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking
statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may
differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation,
ability to obtain financing and regulatory and shareholder approval for anticipated actions.
Contact: Media Contact: (727) 228-3994 Apotheca Biosciences http://www.apothecabio.com info@apothecabio.com Twitter - @apotheca Facebook – apotheca Telegram- apotheca
